Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease (Q42635425)

4 November 2017

title

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease (English)

1 reference

4 November 2017

1 reference

1 reference

2

1 reference

4 November 2017

Teddy Kosoglou

1

1 reference

4 November 2017

Bharath Kumar

3

1 reference

4 November 2017

Paul Statkevich

4

1 reference

4 November 2017

Fengjuan Xuan

5

1 reference

4 November 2017

Lei Ma

6

1 reference

4 November 2017

Lisa K Jennings

7

1 reference

4 November 2017

James E Schiller

8

1 reference

4 November 2017

Ronald B Langdon

9

1 reference

4 November 2017

David L Cutler

10

1 reference

4 November 2017

publication date

8 February 2012

1 reference

European Journal of Clinical Pharmacology

4 November 2017

published in

1 reference

4 November 2017

volume

68

1 reference

4 November 2017

issue

7

1 reference

4 November 2017

page(s)

1049-1056

1 reference

Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

21 January 2018

Unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Platelet activation and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Recent advances in antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Platelet thrombin receptor antagonism and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Protease-activated receptor 1 is the primary mediator of thrombin-stimulated platelet procoagulant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Role of platelets in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

G-protein coupled receptor antagonists-1: protease activated receptor-1 (PAR-1) antagonists as novel cardiovascular therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)-

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-012-1217-6

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

21 January 2018

1 reference

12 December 2020

Safety of the Novel Protease-Activated Receptor-1 Antagonist Vorapaxar in Japanese Patients with a History of Ischemic Stroke

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

1 reference

12 December 2020

Thrombin functions during tissue factor-induced blood coagulation

1 reference

12 December 2020

10.1007/S00228-012-1217-6

Identifiers

DOI

1 reference

4 November 2017

1 reference